Company / Accounts Receivable
LIPELLA PHARMACEUTICALS INC. Accounts Receivable History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$84.7K
FY2024
5-year range
$32.3K / $113.7K
FY2022-FY2024
Trend
+162.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $113,655 to $84,713 over the past 2 years.
Based on SEC 10-K filings.
$84,713 in FY2024.
Declined from $113,655 to $84,713 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, accounts receivable increased 162.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score -8.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $84.7K | +162.4% |
| FY2023 | $32.3K | -71.6% |
| FY2022 | $113.7K | - |
As of FY2024 · SEC Form 10-K · Last checked Jun 29, 2026